Literature DB >> 23239212

AA amyloidosis: Mount Sinai experience, 1997-2012.

Daniel Bunker1, Peter Gorevic.   

Abstract

BACKGROUND: AA amyloidosis is a systemic disease characterized by the extracellular deposition of amyloid fibrils derived from the acute-phase reactant serum amyloid A protein. It is typically a consequence of chronic inflammatory conditions like rheumatoid arthritis or Crohn's disease, although more patients are being identified who have more unusual causes or no known inflammatory stimulus.
METHODS: We performed a retrospective chart review of all patients with AA amyloidosis seen at Mount Sinai during the period of 1997-2012. Particular attention was paid to the patients' underlying diseases, extent of organ involvement, levels of inflammatory markers and proinflammatory cytokines, presence of pyrin gene mutations, and outcomes.
RESULTS: Forty-three patients were seen at Mount Sinai with AA amyloidosis during this period. The most common underlying diseases were rheumatoid arthritis (21%) and Crohn's disease (16%), though 21% of patients were considered to have idiopathic AA amyloid after an extensive search found no underlying inflammatory disease. Almost all patients (95%) had renal involvement based on biopsy or clinical criteria, with 19 patients (44%) eventually requiring dialysis and 5 (12%) undergoing renal transplantation. Inflammatory markers were elevated in most patients; however, interleukin-6 was the only consistently elevated cytokine. Three patients (of 9 tested) were found to be positive for the E148Q pyrin gene mutation.
CONCLUSIONS: Our study confirms the increasing number of patients being seen with idiopathic AA amyloidosis. More research is needed to determine if these patients have an underlying genetic susceptibility encoded in pyrin or other genes. Our study also confirms the dominance of renal disease in this population. The elevated levels of interleukin-6, in comparison with other cytokines, could represent a therapeutic target.
© 2012 Mount Sinai School of Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239212     DOI: 10.1002/msj.21342

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  8 in total

1.  Amyloid and inflammation.

Authors:  Peter D Gorevic
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-25       Impact factor: 11.205

2.  A rare cause of AA amyloidosis and end-stage kidney failure: Answers.

Authors:  Mehmet Taşdemir; Sezen Yılmaz; Zeliha Füsun Baba; Ilmay Bilge
Journal:  Pediatr Nephrol       Date:  2018-11-19       Impact factor: 3.714

3.  Heroin Use Is Associated with AA-Type Kidney Amyloidosis in the Pacific Northwest.

Authors:  Arjun Sharma; Priyanka Govindan; Mirna Toukatly; Jack Healy; Connor Henry; Steve Senter; Behzad Najafian; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-15       Impact factor: 8.237

4.  Mean platelet volume as a potential predictor of proteinuria and amyloidosis in familial Mediterranean fever.

Authors:  Hale Sakallı; Oznur Kal
Journal:  Clin Rheumatol       Date:  2013-04-17       Impact factor: 2.980

5.  Renal transplantation in secondary amyloidosis associated with tuberculosis.

Authors:  Vivek B Kute; Aruna V Vanikar; Himanshu V Patel; Manoj R Gumber; Pankaj R Shah; Pranjal R Modi; Hargovind L Trivedi
Journal:  Case Rep Transplant       Date:  2013-12-25

Review 6.  Serum Amyloid A Protein-Associated Kidney Disease: Presentation, Diagnosis, and Management.

Authors:  Jordan Thorne; David Clark; Laurette Geldenhuys; Keigan More; Amanda Vinson; Karthik Tennankore
Journal:  Kidney Med       Date:  2022-06-26

7.  Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF.

Authors:  Sedat Yılmaz; Emre Tekgöz; Muhammet Çınar
Journal:  Eur J Rheumatol       Date:  2018-07-20

8.  Trifascicular block as primary presentation of the cardiac amyloidosis; A rare case report.

Authors:  Mohsen Yaghubi; Hossein Dinpanah; Fahimeh Ghanei-Motlagh; Samaneh Kakhki; Reza Ghasemi
Journal:  ARYA Atheroscler       Date:  2018-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.